Table 1.
—Participant Characteristics
| Characteristica | No. (%) |
| Age, mean (range), y | 11 (5-17) |
| Male patient | 79 (57) |
| Black patient | 125 (91) |
| Annual household income < $30,000/y (n = 127) | 87 (69) |
| Parental education | |
| Not a high school graduate | 42 (30) |
| High school graduate | 43 (31) |
| Some college | 53 (38) |
| Insurance (n = 136) | |
| Public | 117 (86) |
| Private or self pay | 19 (14) |
| Total IgE, median (IQR), kU/L (n = 136) | 170 (50-450) |
| Atopic (≥ 1 positive skin test) | 124 (90) |
| Allergy skin testing results | |
| Cat | 89 (64) |
| Rat | 83 (60) |
| Cockroach | 81 (59) |
| Dust mite | 77 (56) |
| Mouse | 71 (51) |
| Dog | 22 (16) |
| Spirometry,b mean (SD) | |
| FEV1, % predicted | 94.4 (17.7) |
| FEV1/FVC % | 80.7 (9.6) |
| Reversible (≥ 12%) | 34 (27) |
| Feno, median (IQR), ppb | 32 (16-61) |
| Use of controller medications for asthma | 97 (70) |
| ED visit in the past 12 mo | 111 (80) |
| Hospitalization in the past 12 mo | 26 (19) |
| ED visit or hospitalization | 116 (84) |
| Maximum symptom days/2 wk,c mean ± SD | 3.3 ± 4.0 |
| Days of SABA use/2 wk, mean ± SD | 4.1 ± 4.9 |
Feno = fractional exhaled nitric oxide; IQR = interquartile range; ppb = parts per billion; SABA = short-acting β agonist.
a
n = 138 patients.
b
Valid data for 126 participants overall and 124 participants for bronchodilator effects.
c
Maximum days of slowed activity, with exercise-related or nocturnal symptoms.